Reappraisal of the management of Vogt-Koyanagi-Harada disease: sunset glow fundus is no more a fatality

Abstract

Vogt-Koyanagi-Harada (VKH) disease is a primary autoimmune stromal choroiditis. Aim of the study was to gather a body of evidence from the literature and from experts that systemic corticosteroid combined with non-steroidal immunosuppressive therapy should become the standard of care in initial-onset VKH disease.